<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3C8A544E-00F6-4FA9-B14D-1F04B5B50A56"><gtr:id>3C8A544E-00F6-4FA9-B14D-1F04B5B50A56</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1B2A7C02-2FBB-426E-AFC0-62080BF98185"><gtr:id>1B2A7C02-2FBB-426E-AFC0-62080BF98185</gtr:id><gtr:firstName>Geoff</gtr:firstName><gtr:surname>Berg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D1DD1D90-1280-4E83-9E91-A5C1B4D74A1F"><gtr:id>D1DD1D90-1280-4E83-9E91-A5C1B4D74A1F</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:otherNames>George</gtr:otherNames><gtr:surname>Oldroyd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EB62FC1C-9971-403E-8AB2-5320A6FB9E9B"><gtr:id>EB62FC1C-9971-403E-8AB2-5320A6FB9E9B</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/27AAF6C2-069D-4BD2-AADC-D947F93F4322"><gtr:id>27AAF6C2-069D-4BD2-AADC-D947F93F4322</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Nicklin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FF3D9AC5-E57D-472C-A10B-D9B55FC2D4F2"><gtr:id>FF3D9AC5-E57D-472C-A10B-D9B55FC2D4F2</gtr:id><gtr:firstName>Niko</gtr:firstName><gtr:surname>Tzemos</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9ED0F1CA-38BA-4436-91AC-421777202D73"><gtr:id>9ED0F1CA-38BA-4436-91AC-421777202D73</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Norrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001147"><gtr:id>857CC1FB-4B21-4D7D-88A5-949C80FCA961</gtr:id><gtr:title>Developmental Clinical Studies - Gene Therapy For Vein Graft Failure</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001147</gtr:grantReference><gtr:abstractText>Failure rates for heart bypass grafts using veins remain very high and represent a major clinical problem that lacks a drug-based treatment. Our prior studies have demonstrated the unique ability of gene therapy (the use of a patient s genes to treat the disease) to prevent the vein getting blocked which is associated with graft failure. We wish to perform a clinical trial in patients undergoing bypass grafting and assess the safety and beneficial effect of gene therapy.</gtr:abstractText><gtr:technicalSummary>Our clinical trial application is based on a gene therapy approach for prevention of vein graft failure. The long term failure of bypass grafting using autologous saphenous vein remains a major clinical burden on the NHS. Preventing neointima formation in the immediate time points post-grafting is likely to have a major impact on the frequency of long term graft failure. We have developed a gene therapy approach using a replication-defective adenovirus vector that overexpresses the therapeutic gene ?tissue inhibitor of metalloproteinases-3 (TIMP-3)? that significantly attenuates neointima formation in human saphenous vein ex vivo and pig vein grafts in vivo. We propose a phase I/II clinical trial to assess the safety and efficacy of this approach in patients undergoing elective coronary bypass graft surgery. This first-in-man ex vivo approach maximises target vascular gene transfer while minimising systemic vector dissemination post-grafting. Our trial is designed with key milestones with firm efficacy endpoints.</gtr:technicalSummary><gtr:fund><gtr:end>2019-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4029941</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>GSK Biologicals SA</gtr:department><gtr:description>GSK</gtr:description><gtr:id>65CE2555-A0C3-48DB-8369-B97AA3491092</gtr:id><gtr:impact>no outcome yet</gtr:impact><gtr:partnerContribution>To use their cell line to try and rescue this virus</gtr:partnerContribution><gtr:piContribution>GSK have agreed to partner to make the virus for the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Glasgow Science Festival 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BE8E3B71-A5AD-46E4-B34F-ACA0D6A1B4A4</gtr:id><gtr:impact>We informed the public from children to adults about the concept of using viruses in therapy for cardiovascular disease

Feedback has been extremely positive</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Science Festival 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>596EA23D-CA3E-40C6-8437-1A5ED31CE88F</gtr:id><gtr:impact>A dissemination of information on cardiovascular gene therapy, science and implementation of clinical trial therapies using viruses to school students

n/a</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Researcher Night</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B78ED2C7-713E-425A-8D6C-81D618898D89</gtr:id><gtr:impact>Interactive discussion about viruses in cardiovascular disease with a broad range of ages from schoolchildren to adults leading to improved knowledge, further questions and amazing interest

Feedback has been extremely positive</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.gla.ac.uk/news/headline_341772_en.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Virus is in stages of GMP production for the implementation of the trial</gtr:description><gtr:id>D6D910E8-80F5-4C74-BBED-7E7CA036EA7C</gtr:id><gtr:impact>Clinical trial not performed yet.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AdTimp3 for Gene Therapy</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G1001147</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>